Surat-based custom synthesis producer of specialty chemical, Anupam Rasayan India, has agreed to obtain 100% equity stake in Jayhawk Fine Chemicals Corporation, a US-primarily based specialty chemical corporation, for a purchase consideration of round $150-mn (Rs. 1,348-crore).
The purchase consideration accounts for payment in opposition to the equity value of Jayhawk and ongoing loans payable to the prevailing shareholders. With refer to ~$16-mn of cash and cash-like items for Jayhawk as of June-25, the purchase consideration interprets to an enterprise value of ~$134-mn. The acquisition be financed thru a mix of internal accruals, debt and quasi equity from a main global investment management firm.
Founded in 1941 and situated in Kansas, Jayhawk Fine Chemicals is a part of the CABB Group and is occupied in custom production of superior intermediates, active ingredients, and high-performance materials.
Anupam Rasayan stated that the purchase will assist increase its global CDMO presence and set up a strong initial presence within the US & world specialty chemical market.
This acquisition marks Anupam’s entry into onshore production in the US. Jayhawk’s US operations and consumer base gives Anupam a direct access to main end-markets and leading multinational customers, considerably improving its global reach and visibility.
The deal will increase Anupam’s polymer portfolio, including high-value dianhydrides and polyimide intermediates to its presenting. These products have essential programs across semiconductors and high-overall performance materials.
Over the past few years, Anupam has Sequentially fortified the value chain – beginning with purchasing of Tanfac, which acquired raw material procuring and ensured backward integration, specifically in fluorination chemistry.
“Now, with Jayhawk, we move forward in the value chain, towards the end applicatons, production key N-1 molecules for these crucial sectors,” stated Mr. Anand Desai, Managing Director, Anupam Rasayan.
The combination of Jayhawk’s product portfolio and Anupam’s procedure expertise lets in for ahead integration throughout main molecules, allowing new downstream possibilities, he delivered.
Commenting at the intent for the divestment, Mr. Tobias Schalow, CEO, CABB Group, stated, “We have evolved a scalable growth platform in Pharma and Life Science specialties, which we are able to similarly develop and amplify, and shift away from industrial applications, electronics and semiconductors with this transaction.”
